Precise Polymer Delivery Restores PTEN in Lung Cancer Cells, Inhibiting Tumor Growth by 81%
Background
Restoring the function of PTEN (Phosphatase and Tensin Homolog), a tumor suppressor gene, is a promising strategy for treating non-small cell lung cancer (NSCLC). While small molecule compounds and DNA-based gene therapies have been actively explored, their low target specificity and potential for genomic alterations have been limiting factors. Messenger RNA (mRNA) therapeutics have emerged as an attractive alternative, as they can transiently express target proteins without altering the patient's genome. However, mRNA, with its large molecular size and strong negative charge, is susceptible to degradation in vivo. Existing delivery systems, such as lipid nanoparticles (LNPs), primarily accumulate in the liver after administration, resulting in poor delivery to lung cancer cells. Therefore, a new system is needed to safely and selectively deliver mRNA to the lung tissue where cancer cells are located.
Restoring the tumor suppressor PTEN (phosphatase and tensin homolog) offers a promising therapeutic strategy for nonsmall cell lung cancer (NSCLC). In particular, mRNA-based therapy provides a compelling alternative to small molecules and DNA-based gene therapy, combining high specificity with an excellent safety profile. However, its clinical translation hinges on the development of safe and efficient delivery systems. In this study, we present a rationally designed diblock copolymer that mediates highly effective PTEN mRNA delivery both
In the clinical setting, this technology could serve as a rescue therapy for patients who have developed resistance to conventional chemotherapy or targeted therapies. For example, administering this polymer-based mRNA to NSCLC patients with PTEN loss, a tumor suppressor gene, could be a viable scenario. If developed as an inhaled formulation for direct administration to the patient's lungs, it could enhance the efficiency of targeting cancer cells while maximizing patient convenience. The mRNA delivered into cells could temporarily and completely restore the function of the tumor suppressor gene, inducing cancer cell apoptosis or overcoming drug resistance. This is expected to provide a safe and sustainable treatment option for patients for whom intravenous administration was difficult due to liver toxicity.